Tagraxofusp-erzs
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Uma Maveli[2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
WARNING: CAPILLARY LEAK SYNDROME
See full prescribing information for complete Boxed Warning.
|
Overview
Tagraxofusp-erzs is a antineoplastic biologic response modulator that is FDA approved for the treatment of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include Some adverse reactions that occur in patients undergoing treatment with Tagraxofusp-erzs are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight gain. Some lab abnormalities that occur include decreases in albumin, platelets, hemoglobin, calcium, sodium, and increases in glucose,ALT, and AST..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
ELZONRIS is indicated for:
- ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm
- It is a CD123-directed cytotoxin for the treatment of the specific cancer
- This medication is administered to adult patients and pediatric patients 2 years and older with this type of cancer
Limitations of Use
Dosing Considerations
- Before initiating treatment of ELZONRIS, guarantee that the serum albumin is greater than or equal to 3.2 g/dL
- Patients with H1- histamine antagonist, H2- histamine antagonist, corticosteroids, and acetaminophen should be premedicated about 1 hour before initiating the ELZONRIS dose
- The patients should be monitored after the first cycle of administration in an in person setting for up to 24 hours after initiation of the last infusion
- The following cycles should be administered in an inpatient setting as well, or in a setting containing the equipment needed to treat and monitor the patients hematopoietic malignancies. Patients should be monitored for 4 hours following the previous infusion.
Preparation of ELZONRIS
- Before initiating dosage, make sure the following components are available to provide the patient treatment safely and successfully: 1 empty 10 mL sterile vial, 0.9% of sodium chloride injection, 3 10 mL sterile syringes, 1 mini-bifuse Y-connector, microbore tubing, and 1 0.2 micron polyethersulfone in-line filter
- Elzonris should be thawed in a room with the temperature ranging from 15°C and 25°C (59°F and 77°F), for 15-30 minutes in its original container and carton. The thawed medication is permitted to be exposed to room temperature for 1 hour prior to dosage preparation. THE VIAL SHOULD NOT BE REFROZEN AFTER IT HAS BEEN THAWED.
- The presentation of thawed Elzonris should be clear and colorless liquid that might consist of a few white to translucent particles.
- Preparation should be done using aseptic techniques. The steps of preparation are as follows:
Prepare 10 mL of 100 mcg/mL Elzonris:
- Use the sterile 10 mL syringe to transfer 9 mL of 0.9% sodium chloride injection,
- Gently swirl the vial to make sure all the contents have been mixed properly. Then, remove the cap from the vial to use the sterile 1 mL syringe to 1 mL of the thawed Elzonris
- Then transfer the 1 mL of Elzonris to the 10-mL vial that contains the sodium chloride injection. To mix the contents, slowly flip it back and forth. The final concentration is 100 mdg/mL.
Prepare the Elzonris infusion set to initiate treatment
- Calculate the weight-based required volume of the patient for the required volume of the diluted Elzonris (100 mcg/mL)
- Repeat all of step one if the required weight-based dosage is above 10 mL of diluted ELZONRIS (100 mcg/mL).
- Fill the syringes with at least 3 mL of the 0.9% sodium chloride injection. This will be used to flush the administration set after the dose has been administered to the patient.
- Connect the saline flush syringe to an arm of the Y-connecter (see above for required materials). Make sure the clamp is close, and then connect the product syringe to the other arm of the Y-connecter. Finally, connect the final end of the Y-connecter to the microbore tube.
- Use the supply side of the 0.2 micron filter and put it to the side.
- Now, unclamp the arm of the Y-connector that contains the product syringe, and prepare the entire infusion set. Cap the the filter and reclamp the Y-connector line on the product side.
Administration of ELZONRIS
- The recommended dose for patients is 12 mcg/kg that is administered intravenously for a period of 15 minutes daily once. The medication should be administered on days 1 and 5 of a 21-day cycle.
- Patients should continue the treatment until the disease progresses, stops, or the patient suffers from unacceptable toxicity
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding ALPELISIB Off-Label Guideline-Supported Use and Dosage (Adult) in the drug label.
Non–Guideline-Supported Use
There is limited information regarding ALPELISIB Off-Label Non-Guideline-Supported Use and Dosage (Adult) in the drug label.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding ALPELISIB FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding ALPELISIB Off-Label Guideline-Supported Use and Dosage (Pediatric) in the drug label.
Non–Guideline-Supported Use
There is limited information regarding ALPELISIB Off-Label Non-Guideline-Supported Use and Dosage (Pediatric) in the drug label.
Contraindications
- Patients may be advised to withhold this medication for a certain time period because of severe hypersensitivity to Alpelisib or any of its components (check components on the label or talk to a medical professional for more information)
Warnings
|
WARNING: CAPILLARY LEAK SYNDROME
See full prescribing information for complete Boxed Warning.
|
Severe Cutaneous Reaction
- Less than 2 percent of the patients have shown these possibly lethal reactions connected to the skin and mucous membranes that could be linked to eyes, ears, nose, mouth, lips etc
- Diseases including Stevens-Johns Syndrome (0.4% of the patients) and Erythema Multiforme (1.1% of the patients) were linked to patients consuming or using this medication
- Treatment with Piqray will not be initiated in patients with histories of this disease. Additionally patients who have had severe cutaneous reactions while undergoing treatment with this disease will not be reintroduced to Piqray
- If symptoms appear in patients, temporarily discontinue the medications immediately
- If the signs/ symptoms are confirmed to be associated with Severe Cutaneous Reactions, patients will have to permanently discontinue the medication
- If the reactions are not associated with Severe Cutaneous Reactions, there may be a need of dose modifications
Hyperglycemia
- Hyperglycemia has been reported in 65% of patients utilizing this medication. Some signs and symptoms of this disease could include excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss.
- Ketoacidosis was reported in 0.7% of patients
- Studies have shown patients usually show signs of hyperglycemia a median time of 15 days into treatment
- It is advised for patients to be tested to track FPG, HbA1c levels, and to optimize the blood glucose before initiating Piqray treatment
- The FPG and blood glucose levels should be monitored for at least the first 8 weeks, once a week. Later, there should be a checkup every 2 weeks, and the time indicated by the doctor.
- Patients should consider meeting with a professional with expertise in treating hyperglycemia. They may be able to help counsel the patients on lifestyle changes.
- Clinical studies have not tested the effect of Piqray on patients with Type 1 diabetes and uncontrolled Type 2 diabetes. Therefore, the safety of combining these diseases with Piqray has not yet been established. Patients should check with a medical practitioner and weight the pros and cons.
- Patients with controlled Type 2 diabetes and Diabetes Mellitus were included, and it is advised to closely monitor these patients using Piqray.
- Patients may have to temporarily or permanently discontinue or reduce dose and treatment of Piqray based on the severity of the hyperglycemia present.
Pneumonitis
- Pneumonitis was discovered in 1.8% of the patients who were treated with Piqray
- Common forms of pneumonitis present within these patients are acute interstitial pneumonitis and interstitial lung disease
- If patients begin showing signs and symptoms of pneumonitis, immediately discontinue the drug until the presence of the disease is either confirmed or denied.
- Symptoms of non-infectious pneumonitis include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. There are no studies performed on patients with infectious or neoplastic pneumonitis because there are no means for an appropriate investigation.
- If patients are diagnosed with pneumonitis, discontinue the drug immediately. If they continue to have worsening symptoms, contact a medical professional immediately.
Diarrhea
- Severe diarrhea, that resulted in dehydration and acute kidney injury, have been present in 58% of patients undergoing treatment with Piqray.
- In a study, 6% of patients required dose reduction, and 2.8% of the people were required to permanently discontinue the drug. There were a total of 164 patients that experienced a case of diarrhea, and 63% of the patients needed to take anti-diarrheal medications.
- Patients may have to temporarily or permanently discontinue the drug, or reduce the dose if a problem with diarrhea persists or becomes severe
Embryo-Fetal Toxicity
- Female rats and rabbits pregnant were administered doses of Piqray. These studies have shown the effect Piqray can have on the mothers, and fetuses. It caused adverse developmental outcomes including embryo-fetal mortality, loss of fetal weight, and increased cases in fetal malformation.
- Pregnant females, and females with reproductive potential should be advised to use effective contraception during treatment, and 1 week after the last dose. Male patients should also use effective contraception and condoms during treatment and for 1 week after the last dose.
Monitoring Disease Manifestations after ALPELISIB Discontinuation
- Patients are advised to reach out to healthcare professionals if any adverse reactions persist.
- Patients should talk to their healthcare provider for more information on routine checkups after discontinuing treatment
Infusion Reactions
- There is limited information on infusion reactions pertaining to Alpelisib. Contact a doctor immediately if an adverse reactions occur (see adverse reactions)
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Tagraxofusp-erzs Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Alpelisib Postmarketing Experience in the drug label.
Drug Interactions
CYP3A4 Inducer
Administering Alpelisib along with a CYP3A4 Inducer may result in a decrease in Alpelisib concentration, and a decrease in effectiveness and activity. Patients should avoid co-administering Alpelisib with strong CYP3A4 inducers.
BCRP Inhibitors
Administering Alpelisib with BCRP inhibitors increases Alpelisib concentrations that can result in the risk of toxicity in patients. Coadministering Alpelisib with BCRP inhibitors should be avoided. If it is not possible to completely avoid, patients should be closely monitored for adverse reactions.
CYP2C9 Substrates
Administering Alpelisib with CYP2C9 substrates may result in reduced plasma concentrations of the drugs it is administered with. It is advised to monitor patients closely for a decrease in plasma concentrations because that can cause reduced activity and effectiveness of the drugs.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There are no available data on ALPELISIB use in pregnant women to inform a drugassociated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Tagraxofusp-erzs in women who are pregnant.
Labor and Delivery
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Nursing Mothers
Women should not breastfeed while undergoing treatment with this medication and for 1 week after the last dose.
Pediatric Use
The safety and efficacy of ALPELISIB for the treatment of PNH in pediatric patients have not been established.
Geriatic Use
There were 117 patients in Solar-1 Clinical Trial that were of age 65 or older, and of that 75 patients were of the age 75 and up. There was a higher percentage of cases of Grade 3 or 4 hyperglycemia (44%) in patients of the age 65 and older compared to the incidence in patients less than the age of 65 (32%). Studies did not show a significant gap in effectiveness of Piqray comparing patients less than 65 years, and patients greater than 65 years of age.
Gender
There is no FDA guidance on the use of ALPELISIB with respect to specific gender populations.
Race
There is no FDA guidance on the use of ALPELISIB with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of ALPELISIB in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of ALPELISIB in patients with hepatic impairment.
Females of Reproductive Potential and Males
FDA guidance suggests healthcare providers should advise and counsel all patients with reproductive potential that ALPELISIB may impair fertility.
Immunocompromised Patients
There is no FDA guidance one the use of ALPELISIB in patients who are immunocompromised.
Administration and Monitoring
Administration
- Piqray is administered orally
Monitoring
There is limited information regarding Tagraxofusp-erzs Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Tagraxofusp-erzs and IV administrations.
Overdosage
In cases of overdosage with Piqray, patients showed a similar set of adverse reactions as indicated in Piqray’s profile. These include hyperglycemia, nausea, rash, and asthenia. There are no established protocol to entail to Piqray overdose. As in all cases of overdose with every drug, “Initiate general symptomatic and supportive measures in all cases” If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
Alpelisib
| |
| Systematic (IUPAC) name | |
| (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | 441.5 g/mol |
| Pharmacokinetic data | |
| Bioavailability | orally |
| Metabolism | hydrolysis reactions and CYP3A4 |
| Half life | 8 to 9 hours |
| Excretion | 39.0L/h |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral use |
Mechanism of Action
- Phosphatidylinositol-3-kinase-a (PI3Ka) mediates cell proliferation as a result of the growth-factor tyrosine kinase pathway activation. PI3Ka’s subunit is mutated in some cancers that make it hyperactive and out of control. Alpelisib inhibits PI3Ka with the highest specificity for it.
Structure
There is limited information regarding ALPELISIB Structure in the drug label.
Pharmacodynamics
There is limited information regarding Tagraxofusp-erzs Pharmacodynamics in the drug label.
Pharmacokinetics
Distribution
- The volume of distribution is 114 L
Elimination
- 36% of Alpelisib is eliminated as the unchanged drug and 32% as the primary metabolite BZG791 through feces. These are for oral doses.
- 2% of the oral dose for Alpelisib is eliminated as the unchanged drug and 7.1% as the primary metabolite through urine
- 81% of an oral dose is eliminated in the faces and 14% in the urine
Specific Populations
- Advise patients to not breastfeed while undergoing treatment with Alpelisib and 1 week after the administration of the last dose
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
- Studies of carcinogenicity and mutagenicity have not yet been performed
Clinical Studies
Study SOLAR-1 (NCT02437318)
- It was a randomized, placebo controlled trial. The trail had two groups of subjects: the patients who got Piqray and fulvestrant vs the patients who got a placebo and fulvestrant. The trial was conducted with 572 patients with “HER2-negative, advanced or metastatic breast cancer whose disease had progressed or recurred on or after an aromatase inhibitor-based treatment.”
- Patients with causes of adverse reactions or adverse reactions such as inflammatory breast cancer, Type 1 diabetes, uncontrolled Type 2 diabetes, or pneumonitis were not included in the study.
- 60% of the enrolled patients had tumors with 1 or more PIK3CA mutations, about 50% had had liver or lung metastases, and about 6% had been previously treated with a CDK4 or 6 inhibitor
- The randomized section was if the patient had liver/ lung metastases and/or been previously treated with a CDK4 or 6 inhibitor
- Division of patients: there were 341 patients in the trial cohort who had at least one PIK3CA mutation and 231 patients in the trial cohorts who did not show the presence of the mutation. Of the patients who had the mutation, about 99% of the patients also had the 1 or more mutations confirmed with a FDA test.
- Patients were put into 2 different groups, so they either received Piqray and fulvestrant or they received a placebo and fulvestrant. The dose of fulvestrant (500 mg) was administered intramuscularly on Days 1 and 15 of the first Cycle, and every first day of the following cycles. The patients continue the treatment in their respective groups until the cancer is shown to progress on radiographs or the patient experiences unacceptable toxicity. The tumors were assessed once every 8 weeks for the first 18 months, and every 12 weeks following the initial period.
- Demographics: the median age of the patients was 63 years, with patients ranging from 25-92 years old. The majority of the patients 999.8%) were women as breast cancer is more common among women. The racial distribution was the following: White patients were 66%, Asian patients were 22%, other/ unknown patients were 10%, Black/ African American patients were 1.4%, and American Indian/ Alaskan Natives were 0.9%.
- The median duration of treatment and exposure to Piqray was about 8.2 months, with an average of 59% of patients’ treatment lasting more than 6 months.
- About 98% of the patients received hormonal therapy prior to initiating the treatment with the study. About 13% of the patients showed signs of primary endocrine resistance which means patients’ diseases progress in less than 6months of endocrine therapy, or relapse within 24 months of initiating therapy. About 72% of patients were observed to have secondary resistance defined as relapse after 24 months consecutive months of hormone therapy, relapsed within 12 months with the same criteria, or disease progression within 6 months of initiating therapy.
- There was no benefit of PFS (Progression-free survival) shown for patients who did not have a PIK3CA tissue mutation. The results for patients with the PIK3CA tissue or plasma mutations showed consistency.
- About 27% of the patients in the 341 patients cohort had died by the evaluation of PFS
How Supplied
- Alpelisib comes in 3 strengths: 50 mg, 150 mg, and 200 mg film-coated tablets
- Patients may be advised to take this medication in strengths of 300 mg, 250 mg, and 200 mg
- 300 mg: They come in cartons with 2 blister packs. Each of the blister packs has a 14-day supply of 28 tablets because the strengths of each tablet is 150 mg.
- 250 mg: This carton contains 2 blister packs. Each of the packs contains a 14-day supply of 28 tablets which means that there are 14 tablets of 200 mg strength and 14 tablets of 50 mg strength in each packet.
- 200 mg: Each carton for a 200 mg strength supply contains one blister pack with 28 tablets for 28 days
Storage
Alpelisib should be stored at 20°C to 25°C (68°F to 77°F), but is allowed to be exposed to temperatures ranging from 15°C and 30°C (59°F and 86°F)
Images
Drug Images
{{#ask: Page Name::Tagraxofusp-erzs |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Tagraxofusp-erzs |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
Severe Hypersensitivity
- Advise patients of the risk of severe hypersensitivity to Alpelisib or any of its contents. Symptoms of severe hypersensitivity include dyspnea, flushing, rash, fever, and/or tachycardia.
- If these signs or symptoms occur, advise patients to call their healthcare professional immediately.
- This may result in discontinuation of the drug
Severe Cutaneous Reaction
- Advise and counsel patients on the signs and symptoms of severe cutaneous reactions: prodrome of fever, flu-like symptoms, mucosal lesions or progressive skin rash)
- These reactions could possibly be lethal if nothing is done about it
- Advise patients to immediately call their doctor if any of these signs/ symptoms occurs.
Hyperglycemia
- Inform patients that there is a possibility of developing hyperglycemia through the treatment of Alpelisib
- Patients must note the importance of monitoring blood-glucose levels “periodically” throughout treatment and for a while after
- Patients should be made aware of the signs and symptoms of hyperglycemia: excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss.
Pneumonitis
- Patients should be asked if they have a history of pneumonitis
- Advise patients to contact the healthcare provider immediately if they experience any respiratory problems including hypoxia, cough, dyspnea, or interstitial infiltrates
- Depending on the severity of the disease, patients may be required to stop treatment and use of Alpelisib
Diarrhea
- Warn patients that treatment of Alpelisib may cause mild to severe diarrhea
- If diarrhea is severe, patients will need to discontinue the drug
- Advise and counsel patients that they may need to take antidiarrheal medication and increase fluids
- Additionally, patients will need to contact their healthcare provider if this problem occurs because severe cases may require patients to permanently discontinue the medication
Embryo-Fetal Toxicity
- Counsel pregnant women and women with reproductive potential on the effects Alpelisib may have on a fetus (see warnings)
- A patient should notify their healthcare provider immediately if they become/ suspect they are pregnant while undergoing treatment with Alpelisib
- Females undergoing treatment with reproductive potential are strongly advised to wear contraception during treatment and 1 week after the last dose. Males/ male patients with female partners of the same caliber are strongly advised to wear protections and contraception during treatment and 1 week after the last dose
Discontinuation
- Patients will be advised to temporarily or permanently discontinue the medication if adverse reactions become severe or persist.
Infusion reactions
- Advise patients that administration of ALPELISIB may result in infusion reactions.
Precautions with Alcohol
Alcohol-Tagraxofusp-erzs interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
ELZONRIS
Look-Alike Drug Names
There is limited information regarding ALPELISIB Look-Alike Drug Names in the drug label.
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.